Human Performance Master Stack: Integrating Peptides, Nootropics & Supplements

The complete performance research framework: foundation supplements, GH peptide optimization, cognitive enhancement, sleep and recovery, and longevity protocols — with budget tiers.

TL;DR

• The performance master stack is a layered system: foundation (supplements) → GH optimization (peptides) → cognitive (nootropics) → recovery → longevity.
• Building from the bottom up matters — peptides perform poorly in a broken hormonal and recovery environment.
• Three budget tiers exist: starter (supplements only), intermediate (+ GH peptides), and advanced (full multi-layer protocol).
• Everything connects: morning and evening timing, HRV monitoring, and bloodwork tracking define the research framework.

Disclaimer: For educational and research purposes only — not medical advice.

The most common mistake in performance research is treating individual compounds as independent interventions rather than components of an integrated physiological system. A GH secretagogue protocol running on a base of chronic sleep deprivation, vitamin D deficiency, and high cortisol produces a fraction of its potential output. A nootropic stack built on top of a non-functioning GH axis will show diminishing returns. The performance master stack presented here is designed as a layered system where each component both functions independently and enhances the layers above it.

This article presents the complete framework: the five layers, the timing protocol, and three budget tiers that allow researchers to build into the full system progressively.

Layer 1: The Foundation — Supplements That Fix the Hormonal Environment

The foundation layer is non-negotiable. These compounds address the most prevalent deficiencies in performance research populations and create the hormonal environment in which everything else operates. Many researchers find that the foundation layer alone — done correctly — produces significant performance improvements that exceed their expectations before any peptide is introduced.

Vitamin D3 + K2 MK-7: The VDR-testosterone connection and calcium trafficking mechanism discussed in detail in the Vitamin D3 + K2 research guide. Research dose: 5,000–10,000 IU D3 with 100–200mcg K2 MK-7, taken with a fat-containing meal.

Magnesium glycinate: GABA receptor co-factor, NMDA modulation, insulin sensitizer, sleep quality optimizer. Severely underconsumed in performance populations. Research dose: 300–400mg elemental as glycinate, split morning and pre-sleep.

Zinc bisglycinate: Aromatase inhibitor, testosterone synthesis co-factor, immune function. Research dose: 25–45mg elemental daily, taken away from calcium.

Omega-3 (EPA + DHA): Membrane fluidity, anti-inflammatory eicosanoid production, muscle damage attenuation. Research dose: 2–4g combined EPA+DHA daily.

Creatine monohydrate: The most evidence-supported ergogenic compound in sports science — 700+ published studies. Creatine increases phosphocreatine stores for ATP regeneration, supports satellite cell function, and has emerging cognitive research. Research dose: 5g/day (no loading phase required at this dose; steady state reached in ~28 days).

Layer 2: GH Optimization — The Peptide Layer

Growth hormone is the body's primary anabolic and lipolytic hormone. GH pulsatility declines ~14% per decade after age 30 (Iranmanesh et al., 1991), contributing to the age-associated increase in body fat, decrease in lean mass, impaired sleep quality, and reduced exercise recovery. GH secretagogues stimulate the pituitary to release more of the body's own GH — a fundamentally different approach from exogenous GH administration.

The most researched GH secretagogue combination: CJC-1295 + ipamorelin

CJC-1295 (with DAC) is a GHRH analog that extends endogenous GHRH signaling, amplifying baseline GH pulse amplitude over a multi-day window due to its albumin-binding extended half-life (~8 days). Ipamorelin is a selective GHSR agonist (mimics ghrelin's GH-releasing effect) with minimal effects on cortisol or prolactin — the cleanest GHS in terms of selectivity profile. Together, they address both the GHRH (amplitude) and ghrelin (pulse frequency) pathways for synergistic GH stimulation.

Research dosing: CJC-1295 with DAC at 2mg/week; ipamorelin at 200–300mcg, 2–3x daily. For reconstitution guidance, see the reconstitution calculator. For half-life context on CJC-1295 and ipamorelin, see the half-life calculator.

Timing: GH is released primarily during deep sleep. Evening administration (60–90 minutes before sleep) of ipamorelin + CJC-1295 aligns with the natural nocturnal GH pulse and produces the greatest pulsatile GH area-under-curve. Do not eat 2 hours before or 30 minutes after injection, as insulin suppresses GH release.

Layer 3: The Cognitive Layer — Nootropics for Performance and CNS Drive

The cognitive layer builds on the hormonal foundation (which itself influences mood, motivation, and mental clarity) by adding direct CNS-acting compounds. Full detail in the Nootropics for Athletes guide.

Morning cognitive stack: Alpha-GPC (600mg, 90 min before training), caffeine + L-theanine (200mg + 400mg), Rhodiola rosea (300mg standardized extract, daily).

CNS drive peptide: Semax (300–600mcg/day intranasal) for researchers seeking BDNF elevation and sustained motivational drive during high training volume phases.

Layer 4: Recovery — Sleep, Tissue Repair, and Mitochondrial Support

Full detail in the Complete Recovery Stack guide.

Tissue repair: BPC-157 (200–500mcg/day, SubQ) and/or TB-500 (2mg 2x/week, SubQ). Use the BPC-157 database entry and TB-500 database entry for full research context.

Sleep architecture: Magnesium glycinate (300mg pre-sleep, shared with foundation layer), 5-HTP (50–100mg), melatonin (0.5–1mg circadian signal).

Mitochondrial recovery: CoQ10 ubiquinol (200mg with fat), omega-3 (shared with foundation layer).

Layer 5: Longevity — NAD+, Senolytics, and Epigenetic Support

The longevity layer targets slower processes — decades-long trajectories rather than session-to-session performance — but the mechanisms overlap with performance biology: NAD+ restoration improves mitochondrial efficiency relevant to training; senolytic clearance reduces SASP-driven inflammation that impairs recovery.

Daily: NMN (250–500mg morning), pterostilbene (100–200mg morning).

Monthly pulse: Fisetin (1,000–2,000mg daily for 2 consecutive days per month, senolytic protocol based on Kirkland research methodology).

Full Protocol Table: Morning and Evening Timing

See Protocol Library for downloadable protocol templates.

Budget Tiers: Starter, Intermediate, Advanced

The starter tier alone — if not currently implemented — will produce meaningful and measurable changes for most researchers in performance populations. The intermediate tier adds the GH optimization layer that most dramatically changes body composition and recovery speed. The advanced tier adds the cognitive, tissue repair, and longevity layers for the most comprehensive protocol.

Frequently Asked Questions

Q: How do you decide when to progress from one budget tier to the next? A: The progression trigger is stabilization at the current tier and evidence of a well-functioning hormonal baseline. Before adding GH peptides, researchers should confirm: consistent sleep of 7–9 hours, vitamin D serum at 40–80 ng/mL, testosterone in a healthy range, and no significant ongoing stressors driving chronically elevated cortisol. Moving to the advanced tier is appropriate when the intermediate tier has been running for at least 8–12 weeks with bloodwork confirming the expected IGF-1 response and no adverse signals.

Q: What bloodwork should a researcher run before starting any peptide protocol? A: A minimum pre-protocol panel includes: complete blood count (CBC), comprehensive metabolic panel (CMP), lipid panel, fasting insulin and glucose, HbA1c, testosterone (total and free), SHBG, LH, FSH, estradiol (E2), IGF-1, TSH (thyroid), 25(OH)D, serum iron/ferritin, and CRP. This baseline allows attribution of any changes — positive or adverse — to the protocol rather than pre-existing conditions. Repeat the relevant markers at 8–12 weeks to assess response.

Q: Is there a risk of GH peptides suppressing natural GH production? A: GH secretagogues (ipamorelin, CJC-1295) work by stimulating the pituitary to release endogenous GH — they do not provide exogenous GH. Because they work through the body's own regulatory feedback mechanisms, they are thought to carry lower risk of pituitary suppression than exogenous GH. Chronic GH secretagogue use does not appear to suppress GH pulse amplitude at commonly used research doses, based on available data. The analogy is to GHRH analogs used clinically: sermorelin, which had FDA approval, was not associated with pituitary suppression in the clinical literature.

Q: How does the master stack interact with HRV tracking? A: HRV is the feedback mechanism that tells you whether the stack is working and whether training load is appropriate. You should expect HRV to trend upward over 4–8 weeks as sleep quality improves (from magnesium + GH peptides), tissue repair improves, and cortisol burden decreases. If HRV is declining despite the protocol, this is a signal to investigate: excessive training volume, insufficient caloric intake, poor sleep despite supplementation, or an individual adverse response to a compound. Use HRV as the objective arbiter of protocol effectiveness.

Get started with your research protocol. → Browse the Protocol Library

For educational and research purposes only. Not medical advice.

Disclaimer: For educational and research purposes only. Nothing in this article constitutes medical advice, diagnosis, or treatment recommendation. All compounds discussed are research chemicals or investigational compounds unless explicitly noted otherwise. Consult a qualified healthcare professional before making any health-related decisions. Researchers must comply with all applicable laws and regulations in their jurisdiction.

Frequently Asked Questions